Christopher D. Owens, M.D.: Decision and Order, 13143-13145 [2018-06089]

Download as PDF 13143 Federal Register / Vol. 83, No. 59 / Tuesday, March 27, 2018 / Notices Controlled substance Drug code amozie on DSK30RV082PROD with NOTICES AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole) ............................................................................................ Heroin ...................................................................................................................................................................... Normorphine ............................................................................................................................................................ U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide) ....................................................... AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)) .......................................................... Alphacetylmethadol except levo-alphacetylmethadol .............................................................................................. Alphameprodine ...................................................................................................................................................... Alphamethadol ......................................................................................................................................................... Benzethidine ............................................................................................................................................................ Betacetylmethadol ................................................................................................................................................... Clonitazene .............................................................................................................................................................. Diampromide ........................................................................................................................................................... Diethylthiambutene .................................................................................................................................................. Dimethylthiambutene ............................................................................................................................................... 1-Methyl-4-phenyl-4-propionoxypiperidine .............................................................................................................. 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine ...................................................................................................... Tilidine ..................................................................................................................................................................... Para-Fluorofentanyl ................................................................................................................................................. 3-Methylfentanyl ...................................................................................................................................................... Alpha-methylfentanyl ............................................................................................................................................... Acetyl-alpha-methylfentanyl ..................................................................................................................................... Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ....................................................................... Beta-hydroxyfentanyl ............................................................................................................................................... Beta-hydroxy-3-methylfentanyl ................................................................................................................................ Alpha-methylthiofentanyl ......................................................................................................................................... 3-Methylthiofentanyl ................................................................................................................................................ Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide) ..................................................... Thiofentanyl ............................................................................................................................................................. Tetrahydrofuranyl fentanyl ....................................................................................................................................... Cyclopropyl Fentanyl ............................................................................................................................................... Fentanyl-related Substance .................................................................................................................................... Amphetamine .......................................................................................................................................................... Methamphetamine ................................................................................................................................................... 1-Phenylcyclohexylamine ........................................................................................................................................ Phencyclidine .......................................................................................................................................................... 4-Anilino-N-phenethyl-4-piperidine (ANPP) ............................................................................................................. Phenylacetone ......................................................................................................................................................... 1-Piperidinocyclohexanecarbonitrile ........................................................................................................................ Alphaprodine ........................................................................................................................................................... Anileridine ................................................................................................................................................................ Cocaine ................................................................................................................................................................... Diphenoxylate .......................................................................................................................................................... Ecgonine .................................................................................................................................................................. Levorphanol ............................................................................................................................................................. Meperidine ............................................................................................................................................................... Meperidine intermediate-A ...................................................................................................................................... Meperidine intermediate-B ...................................................................................................................................... Meperidine intermediate-C ...................................................................................................................................... Dextropropoxyphene, bulk (non-dosage forms) ...................................................................................................... Morphine .................................................................................................................................................................. Levo-alphacetylmethadol ......................................................................................................................................... Alfentanil .................................................................................................................................................................. Remifentanil ............................................................................................................................................................. Sufentanil ................................................................................................................................................................. Carfentanil ............................................................................................................................................................... Tapentadol ............................................................................................................................................................... Fentanyl ................................................................................................................................................................... The company plans to manufacture the above-listed controlled substances as analytical reference standards for distribution to its customers. In reference to drug code 7370 tetrahydrocannabinols the company plans to bulk manufacture as synthetic substances. No other activity for this drug code is authorized for this registration. VerDate Sep<11>2014 18:07 Mar 26, 2018 Jkt 244001 7694 9200 9313 9547 9551 9603 9604 9605 9606 9607 9612 9615 9616 9619 9661 9663 9750 9812 9813 9814 9815 9821 9830 9831 9832 9833 9834 9835 9843 9845 9850 1100 1105 7460 7471 8333 8501 8603 9010 9020 9041 9170 9180 9220 9230 9232 9233 9234 9273 9300 9648 9737 9739 9740 9743 9780 9801 Schedule I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II II II II II II II II II II II II II II II II II II II Dated: March 15, 2018. Susan A. Gibson, Deputy Assistant Administrator. DEPARTMENT OF JUSTICE [FR Doc. 2018–06090 Filed 3–26–18; 8:45 am] Christopher D. Owens, M.D.: Decision and Order BILLING CODE 4410–09–P PO 00000 Drug Enforcement Administration On August 11, 2017, the Acting Assistant Administrator, Diversion Control Division, Drug Enforcement Administration, issued an Order to Show Cause to Christopher D. Owens, M.D. (hereinafter, Registrant), of San Frm 00025 Fmt 4703 Sfmt 4703 E:\FR\FM\27MRN1.SGM 27MRN1 amozie on DSK30RV082PROD with NOTICES 13144 Federal Register / Vol. 83, No. 59 / Tuesday, March 27, 2018 / Notices Francisco, California. GX 2. The Show Cause Order proposed the revocation of Registrant’s DEA Certificate of Registration, and the denial of any applications to renew or modify his registration, or for any other registration, on the ground that Registrant does not ‘‘have . . . state authority to handle controlled substances.’’ Id. at 1. As to the jurisdictional basis for the proceeding, the Show Cause Order alleged that Registrant is registered ‘‘as a practitioner in [s]chedules II through V under . . . Certificate of Registration [No.] FO0414677,’’ at the address of ‘‘University of California, San Francisco, 400 Parnassus Ave[.], #581, San Francisco, CA.’’ Id. at 2. The Order alleged that this ‘‘registration expires by its terms on December 31, 2018.’’ Id. As to the substantive ground for the proceeding, the Show Cause Order alleged that ‘‘[o]n June 22, 2017, the Medical Board of California issued a Default Decision and Order revoking [Registrant’s] Physician’s and Surgeon’s Certificate No. A108740, effective July 21, 2017,’’ and that ‘‘[o]n July 20, 2017, the . . . Board . . . issued an Order denying [his] petition for reconsideration.’’ Id. The Show Cause Order thus alleged that Registrant is ‘‘currently without authority to practice medicine or handle controlled substances in the State of California, the [S]tate in which [he is] registered with the’’ Agency. Id. The Order further asserted that ‘‘based on [his] lack of authority to handle controlled substances in . . . California,’’ his registration is subject to revocation. Id. (citing 21 U.S.C. 824(a)(3); other citations omitted). The Show Cause Order notified Registrant of his right to request a hearing on the allegations or to submit a written statement of position while waiving his right to a hearing, the procedure for electing either option, and the consequence of failing to elect either option. Id. at 2. The Show Cause Order also notified Registrant of his right to submit a Corrective Action Plan pursuant to 21 U.S.C. 824(c)(2)(C). Id. at 3. On August 14, 2017, the Show Cause Order was served on Registrant by providing it to an Assistant Federal Public Defender who was representing Registrant in a pending criminal matter and who stated that she was authorized by Registrant to accept service of the Show Cause Order on his behalf. GX 6. The Attorney also stated that she would provide a copy of the Order to Registrant and subsequently confirmed that she did. Id. at 1–2. On November 28, 2017, the Government filed a Request for Final VerDate Sep<11>2014 18:07 Mar 26, 2018 Jkt 244001 Agency Action (RFAA). Therein, the Government represents that ‘‘[a]t least 30 days have passed since’’ the Show Cause Order ‘‘was served on Registrant.’’ RFAA, at 2. The Government further represents that ‘‘Registrant has not requested a hearing and has not otherwise corresponded or communicated with DEA regarding the Order . . . including the filing of any written statement in in lieu of a hearing.’’ Id. Based on the Government’s representations, I find that 30 days have now passed and Registrant has neither requested a hearing nor filed a written statement while waiving his right to a hearing. I also find that Registrant has not submitted a Corrective Action Plan. Accordingly, I find that Registrant has waived his right to a hearing or to submit a written statement while waiving his right to a hearing; I also find that Registrant has waived his right to submit a Corrective Action Plan. 21 CFR 1301.43(d). I make the following findings of fact. Findings Registrant is the holder of DEA Certificate of Registration No. FO0414677, pursuant to which he is authorized to dispense controlled substances in schedules II through V, as a practitioner, at the registered address of University of California, San Francisco, 400 Parnassus Ave., #581, San Francisco, CA. GX 1, at 1. This Registration does not expire until December 31, 2018. Id. Registrant was also the holder of Physician’s and Surgeon’s certificate No. A108740 issued by the Medical Board of California (hereinafter, MBC or Board). GX 3, at 1. However, on April 25, 2017, a state Administrative Law Judge conducted a hearing at which the ALJ concluded that Registrant ‘‘is unsafe to practice medicine and issued an Interim Suspension Order.’’ Id. at 2. The State ALJ also ordered the Board to file an Accusation against Registrant within 30 days of April 26, 2017. Id. On May 16, 2017, the MBC’s Executive Director filed an Accusation against Registrant, which alleged that ‘‘he selfadministered illicit drugs and has been diagnosed with a substance abuse disorder.’’ Id. at 2, 5. After Registrant failed to respond to the Accusation within the period provided under California law, the Board found Registrant in default and ordered that his medical license be revoked effective on July 21, 2017. Id. at 4–5. While Registrant filed a petition for reconsideration, on July 20, 2017, the Board denied the petition. GX 4. I take official notice of the results of a search PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 of the Board’s license verification web page. See 5 U.S.C. 556(e). That search shows that, as of the date of this Decision, Registrant’s Physician’s and Surgeon’s License remains revoked. See https://search.dca.ca.gov/results. Discussion Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized to suspend or revoke a registration issued under section 823 of the Controlled Substances Act (CSA), ‘‘upon a finding that the registrant . . . has had his State license . . . suspended [or] revoked . . . by competent State authority and is no longer authorized by State law to engage in the . . . dispensing of controlled substances.’’ With respect to a practitioner, DEA has long held that the possession of authority to dispense controlled substances under the laws of the State in which a practitioner engages in professional practice is a fundamental condition for obtaining and maintaining a practitioner’s registration. See, e.g., James L. Hooper, 76 FR 71371 (2011), pet. for rev. denied, 481 Fed. Appx. 826 (4th Cir. 2012); Frederick Marsh Blanton, 43 FR 27616 (1978). The Agency’s rule derives from the text of two other provisions of the CSA: section 802(21), which defines the term ‘‘practitioner,’’ and section 823(f), which sets forth the registration requirements applicable to practitioners. Notably, in section 802(21), Congress defined ‘‘the term ‘practitioner’ [to] mean[ ] a . . . physician . . . or other person licensed, registered or otherwise permitted, by . . . the jurisdiction in which he practices . . . to distribute, dispense, [or] administer . . . a controlled substance in the course of professional practice.’’ 21 U.S.C. 802(21). The text of this provision makes clear that a physician is not a practitioner within the meaning of the CSA if he is not ‘‘licensed, registered or otherwise permitted, by the jurisdiction in which he practices . . . to dispense [or] administer . . . a controlled substance in the course of professional practice.’’ Id. To the same effect, Congress, in setting the requirements for obtaining a practitioner’s registration, directed that ‘‘[t]he Attorney General shall register practitioners . . . if the applicant is authorized to dispense . . . controlled substances under the laws of the State in which he practices.’’ 21 U.S.C. 823(f). Thus, based on these provisions, the Agency held nearly forty years ago that ‘‘[s]tate authorization to dispense or otherwise handle controlled substances is a prerequisite to the issuance and maintenance of a Federal controlled E:\FR\FM\27MRN1.SGM 27MRN1 Federal Register / Vol. 83, No. 59 / Tuesday, March 27, 2018 / Notices substances registration.’’ Blanton, 43 FR at 27617 (revoking physician’s registration based on one-year suspension of his state license) (emphasis added). Based on my finding that Registrant’s Physician’s and Surgeon’s Certificate has been revoked, I find that Registrant is currently without authority to dispense controlled substances under the laws of California, the State in which he is registered. See Cal. Health & Safety Code § 11150 (‘‘No person other than a physician, dentist, podiatrist, or veterinarian . . . shall write or issue a prescription’’ for a controlled substance.); id. § 11210 (‘‘A physician, surgeon, dentist, [or] veterinarian . . . may prescribe for, furnish to, or administer controlled substances to his or her patient when the patient is suffering from a disease, ailment, injury . . . .’’); id. § 11024 (‘‘ ‘Physician,’ ‘dentist,’ ‘podiatrist,’ . . . means persons who are licensed to practice their respective professions in this state.’’); id. § 11352.1(b) (‘‘any person who knowingly and unlawfully dispenses or furnishes a dangerous drug . . . without a license to dispense or furnish these products, shall be guilty of a misdemeanor’’).1 I will therefore order that his registration be revoked and that any pending application to renew or modify his registration, or for any other registration in California, be denied. Order amozie on DSK30RV082PROD with NOTICES Pursuant to the authority vested in me by 21 U.S.C. 824(a) and 28 CFR 0.100(b), I order that DEA Certificate of Registration No. FO0414677 issued to Christopher D. Owens, M.D., be, and it hereby is, revoked. Pursuant to the authority vested in me by 21 U.S.C. 823(f), I order that any pending application to renew or modify this registration, or for any other registration in the State of California, be, and it hereby is, denied. This Order is effective immediately.2 1 See also Cal. Bus. & Prof. Code § 2052 (‘‘any person . . . who diagnoses, treats, operates for or prescribes for any ailment, . . . disease, . . . disorder, injury, or other physical or mental condition of any person, without having at the time of so doing a valid, unrevoked, or unsuspended certificate as provided in this chapter . . . is guilty of a public offense’’); id. § 2051 (‘‘The physician’s and surgeon’s certificate authorizes the holder to use drugs or devices in or upon human beings . . . in the treatment of diseases, injuries, deformities, and other physical and mental conditions). 2 For the same reasons which led the MBC to issue the Interim Suspension Order, I find that the public interest necessitates that this Order be effective immediately. 21 CFR 1316.67. VerDate Sep<11>2014 18:07 Mar 26, 2018 Jkt 244001 Dated: March 14, 2018. Robert W. Patterson, Acting Administrator. [FR Doc. 2018–06089 Filed 3–26–18; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Revised Notice of Lodging of Proposed Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act On March 14, 2018, the Department of Justice published notice of a proposed consent decree that it lodged on February 27, 2018, with the United States District Court for the Southern District of Ohio in the lawsuit entitled United States v. Bridgestone Americas Tire Operations, et al., Case No. 3:18– cv–00054 (S.D. Ohio). It has come to the attention of the Department of Justice that members of the public were unable to access a copy of the proposed consent decree on the Department’s website. As a result, the Department of Justice is now publishing this revised notice, which will give members of the public 30 days from the publication date of this revised notice to review and comment on the proposed consent decree. The proposed consent decree resolves claims of the United States Environmental Protection Agency (‘‘EPA’’) against seven defendants— Bridgestone Americas Tire Operations, LLC; Cargill, Inc.; Flowserve Corporation; Kelsey-Hayes Company; NCR Corporation; Northrop Grumman Systems Corporation, and Waste Management of Ohio (collectively ‘‘Defendants’’)—for response costs and injunctive relief with respect to the North Sanitary (aka ‘‘Valleycrest’’) Landfill Superfund Site in Dayton, Ohio (‘‘Site’’). A complaint, which was filed simultaneously with the proposed consent decree, alleges that the Defendants are liable under Sections 106, 107(a), and 113(g)(2) of the Comprehensive Environmental Response, Compensation, and Liability Act (‘‘CERCLA’’), 42 U.S.C. 9606, 9607(a), and 9613(g)(2). Under the proposed consent decree, the Defendants will perform the remedy selected by EPA to address contamination at the Site by, among other things, designing and constructing a landfill ‘‘cap’’ that will cover approximately 70 acres of the Site. Other significant remedial actions will include the design and construction of a system to address landfill gas, as well as a system to prevent leachate from contaminating groundwater. PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 13145 Additionally, the Defendants will reimburse EPA for its future response costs, but they will not reimburse EPA for its future oversight costs unless and until such costs, together with past responses costs and interim costs incurred before entry of the consent decree, exceed $8.37 million. The proposed consent decree will provide covenants not to sue to the Defendants, as well as to numerous other potentially responsible parties (‘‘Other Settling Parties’’) who have previously entered into settlement agreements with one or more of the Defendants and, in most instances, received indemnifications from them, provided that such Other Settling Parties (listed in Appendix E of the consent decree) submit signature pages agreeing to be bound by the consent decree and, if they own property likely affected by the remedial action, cooperate in the implementation of the consent decree. The publication of this revised notice opens a new period for public comment on the proposed consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer United States v. Bridgestone Americas Tire Operations, et al., Case No. 3:18–cv– 00054 (S.D. Ohio), D.J. Ref. No. 90–11– 3–11076. All comments must be submitted no later than thirty (30) days after the publication date of this revised notice. Comments may be submitted either by email or by mail: To submit comments: Send them to: By email ....... pubcomment-ees.enrd@ usdoj.gov. Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611. By mail ......... During the public comment period, the proposed consent decree may be examined and downloaded at this Justice Department website: https:// www.justice.gov/enrd/consent-decrees. We will also provide a paper copy of the proposed consent decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611. Please enclose a check or money order for $84.50 (338 pages at 25 cents per page reproduction cost) payable to the United States Treasury. For a paper E:\FR\FM\27MRN1.SGM 27MRN1

Agencies

[Federal Register Volume 83, Number 59 (Tuesday, March 27, 2018)]
[Notices]
[Pages 13143-13145]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-06089]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Christopher D. Owens, M.D.: Decision and Order

    On August 11, 2017, the Acting Assistant Administrator, Diversion 
Control Division, Drug Enforcement Administration, issued an Order to 
Show Cause to Christopher D. Owens, M.D. (hereinafter, Registrant), of 
San

[[Page 13144]]

Francisco, California. GX 2. The Show Cause Order proposed the 
revocation of Registrant's DEA Certificate of Registration, and the 
denial of any applications to renew or modify his registration, or for 
any other registration, on the ground that Registrant does not ``have . 
. . state authority to handle controlled substances.'' Id. at 1.
    As to the jurisdictional basis for the proceeding, the Show Cause 
Order alleged that Registrant is registered ``as a practitioner in 
[s]chedules II through V under . . . Certificate of Registration [No.] 
FO0414677,'' at the address of ``University of California, San 
Francisco, 400 Parnassus Ave[.], #581, San Francisco, CA.'' Id. at 2. 
The Order alleged that this ``registration expires by its terms on 
December 31, 2018.'' Id.
    As to the substantive ground for the proceeding, the Show Cause 
Order alleged that ``[o]n June 22, 2017, the Medical Board of 
California issued a Default Decision and Order revoking [Registrant's] 
Physician's and Surgeon's Certificate No. A108740, effective July 21, 
2017,'' and that ``[o]n July 20, 2017, the . . . Board . . . issued an 
Order denying [his] petition for reconsideration.'' Id. The Show Cause 
Order thus alleged that Registrant is ``currently without authority to 
practice medicine or handle controlled substances in the State of 
California, the [S]tate in which [he is] registered with the'' Agency. 
Id. The Order further asserted that ``based on [his] lack of authority 
to handle controlled substances in . . . California,'' his registration 
is subject to revocation. Id. (citing 21 U.S.C. 824(a)(3); other 
citations omitted).
    The Show Cause Order notified Registrant of his right to request a 
hearing on the allegations or to submit a written statement of position 
while waiving his right to a hearing, the procedure for electing either 
option, and the consequence of failing to elect either option. Id. at 
2. The Show Cause Order also notified Registrant of his right to submit 
a Corrective Action Plan pursuant to 21 U.S.C. 824(c)(2)(C). Id. at 3.
    On August 14, 2017, the Show Cause Order was served on Registrant 
by providing it to an Assistant Federal Public Defender who was 
representing Registrant in a pending criminal matter and who stated 
that she was authorized by Registrant to accept service of the Show 
Cause Order on his behalf. GX 6. The Attorney also stated that she 
would provide a copy of the Order to Registrant and subsequently 
confirmed that she did. Id. at 1-2.
    On November 28, 2017, the Government filed a Request for Final 
Agency Action (RFAA). Therein, the Government represents that ``[a]t 
least 30 days have passed since'' the Show Cause Order ``was served on 
Registrant.'' RFAA, at 2. The Government further represents that 
``Registrant has not requested a hearing and has not otherwise 
corresponded or communicated with DEA regarding the Order . . . 
including the filing of any written statement in in lieu of a 
hearing.'' Id.
    Based on the Government's representations, I find that 30 days have 
now passed and Registrant has neither requested a hearing nor filed a 
written statement while waiving his right to a hearing. I also find 
that Registrant has not submitted a Corrective Action Plan. 
Accordingly, I find that Registrant has waived his right to a hearing 
or to submit a written statement while waiving his right to a hearing; 
I also find that Registrant has waived his right to submit a Corrective 
Action Plan. 21 CFR 1301.43(d). I make the following findings of fact.

Findings

    Registrant is the holder of DEA Certificate of Registration No. 
FO0414677, pursuant to which he is authorized to dispense controlled 
substances in schedules II through V, as a practitioner, at the 
registered address of University of California, San Francisco, 400 
Parnassus Ave., #581, San Francisco, CA. GX 1, at 1. This Registration 
does not expire until December 31, 2018. Id.
    Registrant was also the holder of Physician's and Surgeon's 
certificate No. A108740 issued by the Medical Board of California 
(hereinafter, MBC or Board). GX 3, at 1. However, on April 25, 2017, a 
state Administrative Law Judge conducted a hearing at which the ALJ 
concluded that Registrant ``is unsafe to practice medicine and issued 
an Interim Suspension Order.'' Id. at 2. The State ALJ also ordered the 
Board to file an Accusation against Registrant within 30 days of April 
26, 2017. Id. On May 16, 2017, the MBC's Executive Director filed an 
Accusation against Registrant, which alleged that ``he self-
administered illicit drugs and has been diagnosed with a substance 
abuse disorder.'' Id. at 2, 5. After Registrant failed to respond to 
the Accusation within the period provided under California law, the 
Board found Registrant in default and ordered that his medical license 
be revoked effective on July 21, 2017. Id. at 4-5. While Registrant 
filed a petition for reconsideration, on July 20, 2017, the Board 
denied the petition. GX 4. I take official notice of the results of a 
search of the Board's license verification web page. See 5 U.S.C. 
556(e). That search shows that, as of the date of this Decision, 
Registrant's Physician's and Surgeon's License remains revoked. See 
https://search.dca.ca.gov/results.

Discussion

    Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized 
to suspend or revoke a registration issued under section 823 of the 
Controlled Substances Act (CSA), ``upon a finding that the registrant . 
. . has had his State license . . . suspended [or] revoked . . . by 
competent State authority and is no longer authorized by State law to 
engage in the . . . dispensing of controlled substances.'' With respect 
to a practitioner, DEA has long held that the possession of authority 
to dispense controlled substances under the laws of the State in which 
a practitioner engages in professional practice is a fundamental 
condition for obtaining and maintaining a practitioner's registration. 
See, e.g., James L. Hooper, 76 FR 71371 (2011), pet. for rev. denied, 
481 Fed. Appx. 826 (4th Cir. 2012); Frederick Marsh Blanton, 43 FR 
27616 (1978).
    The Agency's rule derives from the text of two other provisions of 
the CSA: section 802(21), which defines the term ``practitioner,'' and 
section 823(f), which sets forth the registration requirements 
applicable to practitioners. Notably, in section 802(21), Congress 
defined ``the term `practitioner' [to] mean[ ] a . . . physician . . . 
or other person licensed, registered or otherwise permitted, by . . . 
the jurisdiction in which he practices . . . to distribute, dispense, 
[or] administer . . . a controlled substance in the course of 
professional practice.'' 21 U.S.C. 802(21). The text of this provision 
makes clear that a physician is not a practitioner within the meaning 
of the CSA if he is not ``licensed, registered or otherwise permitted, 
by the jurisdiction in which he practices . . . to dispense [or] 
administer . . . a controlled substance in the course of professional 
practice.'' Id.
    To the same effect, Congress, in setting the requirements for 
obtaining a practitioner's registration, directed that ``[t]he Attorney 
General shall register practitioners . . . if the applicant is 
authorized to dispense . . . controlled substances under the laws of 
the State in which he practices.'' 21 U.S.C. 823(f). Thus, based on 
these provisions, the Agency held nearly forty years ago that ``[s]tate 
authorization to dispense or otherwise handle controlled substances is 
a prerequisite to the issuance and maintenance of a Federal controlled

[[Page 13145]]

substances registration.'' Blanton, 43 FR at 27617 (revoking 
physician's registration based on one-year suspension of his state 
license) (emphasis added).
    Based on my finding that Registrant's Physician's and Surgeon's 
Certificate has been revoked, I find that Registrant is currently 
without authority to dispense controlled substances under the laws of 
California, the State in which he is registered. See Cal. Health & 
Safety Code Sec.  11150 (``No person other than a physician, dentist, 
podiatrist, or veterinarian . . . shall write or issue a prescription'' 
for a controlled substance.); id. Sec.  11210 (``A physician, surgeon, 
dentist, [or] veterinarian . . . may prescribe for, furnish to, or 
administer controlled substances to his or her patient when the patient 
is suffering from a disease, ailment, injury . . . .''); id. Sec.  
11024 (`` `Physician,' `dentist,' `podiatrist,' . . . means persons who 
are licensed to practice their respective professions in this 
state.''); id. Sec.  11352.1(b) (``any person who knowingly and 
unlawfully dispenses or furnishes a dangerous drug . . . without a 
license to dispense or furnish these products, shall be guilty of a 
misdemeanor'').\1\ I will therefore order that his registration be 
revoked and that any pending application to renew or modify his 
registration, or for any other registration in California, be denied.
---------------------------------------------------------------------------

    \1\ See also Cal. Bus. & Prof. Code Sec.  2052 (``any person . . 
. who diagnoses, treats, operates for or prescribes for any ailment, 
. . . disease, . . . disorder, injury, or other physical or mental 
condition of any person, without having at the time of so doing a 
valid, unrevoked, or unsuspended certificate as provided in this 
chapter . . . is guilty of a public offense''); id. Sec.  2051 
(``The physician's and surgeon's certificate authorizes the holder 
to use drugs or devices in or upon human beings . . . in the 
treatment of diseases, injuries, deformities, and other physical and 
mental conditions).
---------------------------------------------------------------------------

Order

    Pursuant to the authority vested in me by 21 U.S.C. 824(a) and 28 
CFR 0.100(b), I order that DEA Certificate of Registration No. 
FO0414677 issued to Christopher D. Owens, M.D., be, and it hereby is, 
revoked. Pursuant to the authority vested in me by 21 U.S.C. 823(f), I 
order that any pending application to renew or modify this 
registration, or for any other registration in the State of California, 
be, and it hereby is, denied. This Order is effective immediately.\2\
---------------------------------------------------------------------------

    \2\ For the same reasons which led the MBC to issue the Interim 
Suspension Order, I find that the public interest necessitates that 
this Order be effective immediately. 21 CFR 1316.67.

    Dated: March 14, 2018.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2018-06089 Filed 3-26-18; 8:45 am]
 BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.